Innovent Biologics Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of IVBXF for the last semiannual is 484.73 M USD, and it's 24.37% higher compared to the previous semiannual. The net income of H2 23 is -122.93 M USD.